Related Experiment Video

Updated: Aug 6, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Ion channel TRPML2 (MCOLN2) promotes ovarian cancer metastasis and chemoresistance

Shizhang Yang1, Zhenchuan Lei2, Xiaoqiang Yao2

  • 1Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.

Biochemical and Biophysical Research Communications
|July 22, 2026
PubMed
Abstract

Insights

Transient receptor potential mucolipin 2 (TRPML2) is elevated in ovarian cancer, promoting tumor growth and carboplatin resistance. Targeting TRPML2 may offer a new therapeutic strategy for ovarian cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Ovarian cancer poses significant challenges due to metastasis and chemoresistance.
  • Understanding molecular targets is crucial for effective ovarian cancer therapy.
  • The role of the TRPML2 channel in ovarian cancer progression is largely unknown.

Purpose of the Study:

  • To investigate the role of TRPML2 in ovarian cancer progression.
  • To determine the impact of TRPML2 on chemoresistance to carboplatin.
  • To explore TRPML2 as a potential therapeutic target in ovarian cancer.

Main Methods:

  • TRPML2 expression analyzed via immunostaining and western blots.
  • Functional assays included cell viability, colony formation, migration, and transwell assays.
  • Carboplatin resistance evaluated using Cell Counting Kit-8.

Main Results:

  • Elevated TRPML2 expression observed in ovarian cancer cell lines and tissues.
  • High TRPML2 expression correlated with poor prognosis in ovarian cancer.
  • TRPML2 knockdown reduced proliferation, migration, and increased carboplatin sensitivity.

Conclusions:

  • TRPML2 plays a critical role in ovarian cancer progression and carboplatin resistance.
  • Targeting TRPML2 presents a promising therapeutic avenue for ovarian cancer.
Keywords:
ChemoresistanceIon channelMCOLN2Ovarian cancer metastasisTRPML2

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...